Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UNOV vs REGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: UNOV 0 – 6 REGN Matrix Metrics: UNOV 2 – 8 REGN

As of Nov 16, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UNOV carries a Unified Composite Score of 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin), whereas REGN carries 38.6/100 (SELL) at $952.40 (15.3x Forward P/E, 30.4% operating margin).

  • Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. REGN 38.6/100 SELL), REGN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (30.4% vs. N/A operating margin) and revenue trajectory (+36.3% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UNOV vs REGN
UNOV Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 11% Vol
Unified Composite Score
58.7 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.3 · SMA20: $41.59 · SMA50: $41.48
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$952.40
-0.32% 1D
Market Cap $98.8B
TTM Revenue $16.9B
Forward P/E 15.3x
Beta / 30D Vol 0.33β · 55% Vol
Unified Composite Score
38.6 / 100 SELL
Tech 23.0 Fund 43.0 Flow 67.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.5% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $887.40 · SMA50: $818.67

6-Pillar Scorecard Institutional Category Breakdown (UNOV 0 – 6 REGN)

Columns: Metric · UNOV · REGN
1. Valuation Multiples REGN
Forward P/E N/M 15.3x
Trailing P/E N/M 21.1x
PEG Ratio N/M 1.16x
EV / Revenue N/M 5.8x
2. Growth & Scale REGN
Revenue Growth (YoY) N/A +36.3%
Earnings Growth (YoY) N/A +35.5%
TTM Revenue (USD) N/A $16.9B
Market Cap N/A $98.8B
3. Profitability & Quality REGN
Gross Margin N/A 46.7%
Operating Margin N/A 30.4%
Net Profit Margin N/A 28.5%
Return on Equity (ROE) N/A 14.9%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) N/A $3.63B
Cash Flow Margin N/A 21.5%
Net Cash / Leverage N/A ROE $952M Net Cash
Dividend Yield None (0.00%) 0.39%
5. Options & Positioning REGN
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 35.9% (6th %ile)
Put/Call OI Skew N/A 0.38x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity N/A 16.3% of Rev ($2.75B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UNOV (2) vs REGN (8)
Institutional Metric UNOV REGN Criterion Row Edge
Market Capitalization
Scale
N/A $98.8B Larger Scale REGN
Trailing P/E Ratio
Valuation
N/M 21.1x Lower Multiple REGN
Forward P/E Ratio
Valuation
N/M 15.3x Lower Multiple REGN
Revenue Growth (YoY)
Growth
N/A +36.3% Higher Growth REGN
Operating Margin (TTM)
Profitability
N/A 30.4% Higher Margin REGN
Net Profit Margin
Profitability
N/A 28.5% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
N/A 14.9% Higher ROE REGN
52-Week Range Position
Momentum
84% ($37–$42) 90% ($592–$992) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.46β · 11% Vol 0.33β · 55% Vol Lower Realized Risk UNOV
Unified Institutional Score
Composite Signal
58.7 / 100 (HOLD) 38.6 / 100 (SELL) Higher Composite UNOV
Trailing 12M Revenue (USD)
Operating Scale
N/A $16.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.16x PEG · 5.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $3.63B ($952M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +21.41 pp
UNOV: -0.97% · REGN: +20.44%
3M Horizon REGN +17.11 pp
UNOV: +0.44% · REGN: +17.55%
6M Horizon REGN +47.83 pp
UNOV: +3.42% · REGN: +51.25%
1Y Horizon REGN +27.51 pp
UNOV: +9.53% · REGN: +37.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UNOV vs REGN. Trailing 12-month operating profitability (UNOV N/A vs REGN 30.4%) and valuation multiples (UNOV N/M vs REGN 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.

UNOV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
REGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$16.9B
Gross Margin46.7%
Op. Margin30.4%
ROE / Fwd P/E14.9% · 15.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REGN BREAKOUT
52d in phase · OBV ACCUMULATION
Current IV 35.9%
IV Percentile 6th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UNOV Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $98.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published

Investor FAQ UNOV vs REGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UNOV carries a Unified Composite Score of 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin), whereas REGN carries 38.6/100 (SELL) at $952.40 (15.3x Forward P/E, 30.4% operating margin). Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. REGN 38.6/100 SELL), REGN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (30.4% vs. N/A operating margin) and revenue trajectory (+36.3% vs. N/A YoY).

REGN leads the Growth & Scale pillar: UNOV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). On trailing 12-month operating scale, UNOV generates N/A in USD-normalized revenue versus $16.9B for REGN. In operating R&D and SG&A reinvestment, UNOV deploys N/A (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.

REGN screens cheaper on headline valuation multiples. UNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas REGN trades at 15.3x Forward P/E, 21.1x Trailing P/E, 1.16x PEG, and 5.8x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UNOV (N/A ROE) versus REGN (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, UNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 11% Vol realized risk). By comparison, REGN carries 35.9% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.33β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.